Fig. 3

Chemotherapy-DNT combination therapy reduces KG1a engraftment in vivo. a The study protocol for the chemotherapy-DNT combination therapy in NSG mice. b A summary of 3 independently performed experiments (n = 5–10/group per experiment), where NSG mice were engrafted with 4 million KG1a cells i.v., followed by DNT therapy alone, chemotherapy alone, or a combination of the two therapies. Mice were sacrificed 6 weeks post-engraftment for analysis of KG1a engraftment in the bone marrow by gating on human CD45⁺CD34⁺ cells and analyzed by flow cytometry. *, p < 0.05; ****, p < 0.0001